Literature DB >> 8244033

Recombinant DNA procedures for producing small antimicrobial cationic peptides in bacteria.

K L Piers1, M H Brown, R E Hancock.   

Abstract

Natural polycationic antibiotic peptides have been found in many different species of animals and insects and shown to have broad antimicrobial activity. To permit further studies on these peptides, bacterial expression systems were developed. Attempts to produce these peptides with an N-terminal signal sequence were unsuccessful due to the lability of the basic peptides. Therefore, a number of different fusion protein systems were tested, including fusions to glutathione-S-transferase (GST) (on plasmid pGEX-KP), Pseudomonas aeruginosa outer membrane protein OprF (on plasmid pRW5), Staphylococcus aureus protein A (on plasmid pRIT5), and the duplicated IgG-binding domains of protein A (on plasmid pEZZ18). In the first three cases, stable fusion proteins with the defensin, human neutrophil peptide 1 (HNP-1), and/or a synthetic cecropin/melittin hybrid (CEME) were obtained. In the course of these studies, we developed a novel method of purifying inclusion bodies, using the detergent octyl-polyoxyethylene (octyl-POE), as well as establishing methods for preventing fusion protein proteolytic breakdown. Cationic peptides could be successfully released from the carrier protein with high efficiency by chemical means (CNBr cleavage) and with low efficiency by enzymatic cleavage (using factor Xa protease). Fusions of protein A to cationic peptides were secreted into the culture supernatant of S. aureus clones and after affinity purification, CNBr digestion and column chromatography, pure cationic peptide was obtained. CEME produced by this procedure had the same amino acid (aa) content, aa sequence, gel electrophoretic mobility and antibacterial activity as CEME produced by protein chemical procedures.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8244033     DOI: 10.1016/0378-1119(93)90168-3

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  22 in total

Review 1.  Host defence (cationic) peptides: what is their future clinical potential?

Authors:  R E Hancock
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 2.  Antimicrobial peptides: current status and therapeutic potential.

Authors:  Andreas R Koczulla; Robert Bals
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Facilitation of expression and purification of an antimicrobial peptide by fusion with baculoviral polyhedrin in Escherichia coli.

Authors:  Quande Wei; Young Soo Kim; Jeong Hyun Seo; Woong Sik Jang; In Hee Lee; Hyung Joon Cha
Journal:  Appl Environ Microbiol       Date:  2005-09       Impact factor: 4.792

Review 4.  Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?

Authors:  Nicole K Brogden; Kim A Brogden
Journal:  Int J Antimicrob Agents       Date:  2011-07-05       Impact factor: 5.283

5.  Design and identification of a high efficient formic acid cleavage site for separation of fusion protein.

Authors:  Huaguang Zhang; Mei Li; Shuangfeng Shi; Chao Yin; Shirong Jia; Zhixing Wang; Yuhui Liu
Journal:  Protein J       Date:  2015-02       Impact factor: 2.371

6.  Molecular dynamics simulations informed by membrane lipidomics reveal the structure-interaction relationship of polymyxins with the lipid A-based outer membrane of Acinetobacter baumannii.

Authors:  Xukai Jiang; Kai Yang; Bing Yuan; Meiling Han; Yan Zhu; Kade D Roberts; Nitin A Patil; Jingliang Li; Bin Gong; Robert E W Hancock; Tony Velkov; Falk Schreiber; Lushan Wang; Jian Li
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

7.  High-level expression and novel purification strategy of recombinant thanatin analog in Escherichia coli.

Authors:  G-Q Wu; L-X Li; J-X Ding; L-Z Wen; Z-L Shen
Journal:  Curr Microbiol       Date:  2008-06-06       Impact factor: 2.188

8.  Improvement of outer membrane-permeabilizing and lipopolysaccharide-binding activities of an antimicrobial cationic peptide by C-terminal modification.

Authors:  K L Piers; M H Brown; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

9.  Specific binding and chemotactic activity of mBD4 and its functional orthologue hBD2 to CCR6-expressing cells.

Authors:  Johann Röhrl; De Yang; Joost J Oppenheim; Thomas Hehlgans
Journal:  J Biol Chem       Date:  2010-01-12       Impact factor: 5.157

10.  Intramolecular inhibition of human defensin HNP-1 by its propiece.

Authors:  E V Valore; E Martin; S S Harwig; T Ganz
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.